Search results for "anticoagulant agent"

showing 5 items of 5 documents

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct

Management of Antiaggregated and Anticoagulated Patients Scheduled for Thoracic Surgery: Recommendations for Venous Thromboprophylaxis

2017

The management of patients under the effect of antiplatelet or anticoagulant agents is a common challenge in thoracic surgery. Their temporary interruption or continuation needs a balanced assessment between the risk of thrombosis (interruption) and bleeding (continuation). Moreover, most patients must receive an anticoagulant for thromboprophylaxis (mainly a low-molecular-weight heparin). So, it is important to have in mind all surgical and anaesthetic implications of these drugs to take the optimal decision in each case.

medicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentAnticoagulantPercutaneous coronary interventionHeparinmedicine.diseaseThrombosisMechanical heart-valveSurgeryCardiothoracic surgerymedicineStent implantationAnticoagulant AgentIntensive care medicinebusinessmedicine.drug
researchProduct

Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - …

2008

Peripheral Vascular DiseasesLegtrainingTiclopidineAspirinAcetylsalicylic acidanticoagulant agentantithrombocytic agentconsensus document; intermittent claudicatio; training; antiplatelets' therapyintermittent claudicatioIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareClopidogrelantiplatelets' therapyIschemiaDisease ProgressionExercise TestHumansCarotid StenosisUltrasonography Doppler Colorconsensus documentPlatelet Aggregation Inhibitors
researchProduct

Are Anticoagulants and Antiplatelet Agents Important in Thoracic Surgery?

2020

The management of antithrombotic drugs (antiplatelet and anticoagulant agents) is a common challenging issue in patients undergoing thoracic surgery. The procedure can require the temporary interruption of these drugs because of their associated haemorrhagic risk, therefore assuming a thrombotic risk also. The assessment of the balance between both risks gives us their optimal management.

Thrombotic riskAspirinmedicine.medical_specialtyCardiothoracic surgerybusiness.industryAntithromboticmedicineAnticoagulant AgentIn patientIntensive care medicinebusinessOptimal managementmedicine.drug
researchProduct